:format(webp)/cdn.mskdoctors.com/storage/2026/8/K0tLM5AwmOmwkPaB2Har1ULtTxYwLkJY.jpg)
ChondroFiller vs Liquid Cartilage for focal cartilage defectsAn injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.An injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/S6fB5FURIu0CvCfaH3a2BsSKF1F6KZtW.jpg)
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Uh220ymeNrmh32wGZlaNVvxBPMuQySoo.jpg)
Recovery After OATS for Ankle Cartilage RepairOATS (osteochondral autograft transfer) replaces damaged ankle cartilage and bone with a healthy graft from the knee, producing hyaline-like tissue rather than scar tissue; at ten years, graft survival reached 94.9% and functional scores improved from 51.9 to 75.3, though donor-site morbidity affected 6.7–10.8%.OATS (osteochondral autograft transfer) replaces damaged ankle cartilage and bone with a healthy graft from the knee, producing hyaline-like tissue rather than scar tissue; at ten years, graft survival reached 94.9% and functional scores improved from 51.9 to 75.3, though donor-site morbidity affected 6.7–10.8%.
